Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026 16
Figure 4. North America Preventive Vaccines Market, 2016-2026, $ mn 19
Figure 5. Development Stages of Preventive Vaccines 20
Figure 6. Impact of COVID-19 on Business 23
Figure 7. Primary Drivers and Impact Factors of North America Preventive Vaccines Market 25
Figure 8. Primary Restraints and Impact Factors of North America Preventive Vaccines Market 28
Figure 9. Investment Opportunity Analysis 32
Figure 10. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market 35
Figure 11. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue 40
Figure 12. Contribution to North America 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 40
Figure 13. North America Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 41
Figure 14. North America Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 42
Figure 15. North America Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 43
Figure 16. North America Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 44
Figure 17. North America Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 45
Figure 18. North America Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 46
Figure 19. North America Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 47
Figure 20. Breakdown of North America Preventive Vaccines Market by Disease, 2020-2026, % of Revenue 49
Figure 21. Contribution to North America 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 49
Figure 22. North America Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 50
Figure 23. North America Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 51
Figure 24. North America Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 52
Figure 25. North America Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 53
Figure 26. North America Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 54
Figure 27. North America Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 55
Figure 28. North America Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 56
Figure 29. North America Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 57
Figure 30. North America Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 60
Figure 31. Breakdown of North America Preventive Vaccines Market by Administration, 2020-2026, % of Revenue 62
Figure 32. Contribution to North America 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 62
Figure 33. North America Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 63
Figure 34. North America Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 64
Figure 35. North America Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 65
Figure 36. North America Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 66
Figure 37. North America Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 67
Figure 38. Breakdown of North America Preventive Vaccines Market by Patient, 2020-2026, % of Revenue 68
Figure 39. Contribution to North America 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 69
Figure 40. North America Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 70
Figure 41. North America Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 72
Figure 42. Breakdown of North America Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 75
Figure 43. Contribution to North America 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 76
Figure 44. U.S. Preventive Vaccines Market, 2016-2026, $ mn 78
Figure 45. Canada Preventive Vaccines Market, 2016-2026, $ mn 82
Figure 46. Preventive Vaccines Market in Mexico, 2016-2026, $ mn 85
Figure 47. Growth Stage of North America Preventive Vaccines Industry over the Forecast Period 88
Figure 48. Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars) 93
North America preventive vaccines market is expected to grow by 10.42% annually in the forecast period and reach $30.02 billion by 2026 owing to increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines. Highlighted with 51 tables and 48 figures, this 131-page report “North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country. Based on Vaccine Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Live/Attenuated Vaccines • Inactivated Vaccines • Subunit Vaccines • Toxoid Vaccines • Conjugate Vaccines • Recombinant Vector Vaccines • Other Vaccines Based on Disease, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Vaccines for Pneumococcal Disease • Vaccines for Poliovirus • Vaccines for Hepatitis • Vaccines for Influenza • Vaccines for Measles, Mumps, and Rubella (MMR) • Vaccines for Varicella • Vaccines for Human Papilloma Virus • Vaccines for COVID-19 • Vaccines for Other Diseases Based on Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Intramuscular Route • Subcutaneous Route • Oral Route • Intravenous Injection • Other Administration Routes Based on Patient, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Pediatric Vaccines o Pneumococcal o Measles, Mumps, and Rubella (MMR) o Varicella o Hepatitis o Poliovirus o Haemophilus Influenzae B (HIB) o Other Diseases • Adult Vaccines o Influenza o Cervical Cancer o Hepatitis o Zoster o Other Diseases Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca plc Bavarian Nordic A/S China National Biotec Group Company Ltd. CSL Ltd. Daiichi Sankyo Co. Ltd Emergent BioSolutions Inc. GlaxoSmithKline plc Johnson & Johnson Merck & Co. Moderna Inc. Novavax, Inc. Pfizer Inc. Sanofi SA Takeda Pharmaceutical Co. Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More